While the WTO agreements came into force on 1 January 1995, the TRIPS agreement granted WTO members certain transitional periods before they were required to implement all their provisions. Members of developed countries were given one year to ensure that their laws and practices complied with the TRIPS Agreement. Members of developing countries and, under certain conditions, the transitional economy enjoyed a five-year period until the year 2000. The least developed countries were first 11 years old, until 2006 – now they are generally extended until July 1, 2021. The agreement provides for the general obligation that the parties make available to interested parties the legal means to prevent the use of funds in the designation or presentation of a form of property that indicates or indicates that the species of product in question originates from a geographic area other than the actual place of origin in a way that misleads the public as to the geographical origin of the goods. Since the TRIPS agreement came into force, it has been criticized by developing countries, scientists and non-governmental organizations. While some of this criticism is generally opposed to the WTO, many proponents of trade liberalization also view TRIPS policy as a bad policy. The effects of the concentration of WEALTH of TRIPS (money from people in developing countries for copyright and patent holders in industrialized countries) and the imposition of artificial shortages on citizens of countries that would otherwise have had weaker intellectual property laws are common bases for such criticisms. Other critics have focused on the inability of trips trips to accelerate the flow of investment and technology to low-income countries, a benefit that WTO members achieved prior to the creation of the agreement. The World Bank`s statements indicate that TRIPS have clearly not accelerated investment in low-income countries, whereas they may have done so for middle-income countries.
 As part of TRIPS, long periods of patent validity were examined to determine the excessive slowdown in generic drug entry and competition. In particular, the illegality of preclinical testing or the presentation of samples to be authorized until a patent expires have been accused of encouraging the growth of certain multinationals and not producers in developing countries. Some areas are not covered by these agreements. In some cases, the prescribed standards of protection were found to be insufficient. The TRIPS agreement therefore significantly complements existing international standards. With the TRIPS agreement, intellectual property rights have been integrated into the multilateral trading system for the first time and remains the most comprehensive multilateral IP agreement to date. In 2001, developing countries, fearing that developed countries had insisted on too narrow a reading of the TRIPS trip, launched a series of discussions that culminated in the Doha Declaration. The Doha Declaration is a WTO DECLARATION that clarifies the scope of the TRIPS agreement, which states, for example, that TRIPS can and should be interpreted in light of the objective of „promoting access to medicines for all“. Trips-plus conditions, which impose standards beyond TRIPS, have also been verified.
 These free trade agreements contain conditions that limit the ability of governments to introduce competition for generic drug manufacturers.